Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 12 Show results per page	View Search Criteria \| Help With Results

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				C023 ProMune, NCT00070642

Last Modified: 4/15/2004 First Published: 6/1/2002


2.		Phase I/II Study of CpG 7909 and Trastuzumab (Herceptin) in Women With Metastatic Breast Cancer Refractory to Trastuzumab and Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				CPGI-C005 CPGI-C005-CPG7909, CPGI-WIRB-20011156, NCI-V02-1697

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				Over 18				Pharmaceutical / Industry				C016 NCT00043368


4.		CPG 7909 in Patients With Stage IV Renal Cell Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				Over 18				Pharmaceutical / Industry				C010 NCT00043407

Last Modified: 8/1/2007 First Published: 8/24/2004


5.		Phase I/II Randomized Study of CpG 7909 in Patients With Stage IB-IVA Cutaneous T-Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-030104201A CPGI-C014, CPGI-CPG7909-C014, NCT00091208


6.		CPG 7909 Injection in Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				C017 ProMune, NCT00070629

Last Modified: 11/25/2008 First Published: 5/28/2004


7.		Phase II Pilot Study of a Multipeptide (gp100 Antigen, MAGE-3, and Tyrosinase Peptide) Melanoma Vaccine, Montanide ISA 51 and ISA 51 VG, and CpG 7909 in Patients With Resected Stage IIC, III, or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				LAC-USC-10M033 LAC-USC-IRB-942010, NCI-6451, 6451, NCT00085189

Last Modified: 1/16/2008 First Published: 7/1/2002


8.		Phase I Study of CpG 7909 and Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0112032 CPGI-C004-CPG7909, NCI-G02-2086, NCT00040950


9.		Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				18 and over				Other				LUD 2000-018 NCT00112229


10.		NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Closed				18 and over				Other				LUD2003-022;NYU05-120;CUMC9147 NCT00299728

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute